On December 24, 2025, OrbiMed Advisors LLC, through its Director position at Sionna Therapeutics (NASDAQ:SION), sold 33,356 shares for approximately $1.49 million, as reported in an SEC Form 4 filing. Sionna Therapeutics is a clinical-stage biotechnology firm dedicated to developing innovative treatments for cystic fibrosis, focusing on CFTR modulation to meet significant patient needs. The company’s strategy emphasizes proprietary science and targeted therapies, positioning it competitively in the rare disease biopharmaceutical market.
Loading PerspectiveSplit analysis...
